Canakinumab dosing intervals in pediatric colchicine-resistant FMF: outcomes and predictors of successful extension in a real-world cohort
Clicks: 1
ID: 325502
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #190 of 197 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 197 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
OBJECTIVES: Canakinumab is widely used in colchicine-resistant familial Mediterranean fever (FMF), yet data on interval adjustment strategies and predictors of successful extension remain limited. This study evaluated clinical and inflammatory outcomes across dosing interval groups and identified factors associated with successful interval extension. METHODS: This retrospective single-center study included 60 pediatric patients with colchicine-resistant FMF treated with canakinumab. Patients were stratified into stable interval (Group 1, n = 14), successful interval extension (Group 2, n = 24), and unsuccessful interval extension (Group 3, n = 22). Longitudinal C-reactive protein (CRP) trajectories were analyzed using linear mixed-effects models. Clinical outcomes were compared across groups, and predictors of successful interval extension were assessed using multivariable logistic regression with Firth's penalized method as a sensitivity analysis. RESULTS: Following canakinumab initiation, CRP levels declined rapidly and stabilized after month 3, while the median annual attack rate decreased from 7 (4-12) to 1.1 (0.5-2.1) attacks per patient-year. Inflammatory trajectories did not differ across groups. Despite similar CRP dynamics, complete remission rates differed significantly (57.1%, 45.8%, and 27.3% in Groups 1-3, respectively; p = 0.005), and all patients in Group 3 experienced attacks. Arthritis at disease onset was independently associated with successful interval extension (OR = 7.14, 95% CI 1.26-40.41, p = 0.026), with consistent direction in Firth analysis (OR = 5.51, 95% CI 1.08-28.23, p = 0.081). CONCLUSION: Although canakinumab achieves sustained inflammatory suppression, biochemical improvement does not ensure comparable clinical control. Clinical phenotype, particularly arthritis at onset, may guide individualized interval adjustment.
| Reference Key |
openalex_W7203736718
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Nergis Akay, Kenan Barut, Betul Kosa, Ekin Nurhan Mert, Zeynep Torunoğlu Bek, Ece Aslan, Ümit Gül, Elif Kılıç Könte, Mehmet Yıldız, Sezgin Şahin, Özgür Kasapçopur |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag437
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.